What's brewing in CNS?

IN EVERY ISSUE

Recent Activity and Highlights
Executive Moves
Noteworthy Breakthroughs
About Our Firm

NEURO/CNS JOB OPPORTUNITIES

Fairway Consulting Group is conducting a dedicated search for a Vice President of Clinical Development to join our client's innovative team and contribute to the future of neuromuscular treatments.

Reply to this email or CLICK HERE to connect with Michelle for more details.

OPEN JOBS IN CNS CLINICAL DEVELOPMENT

(MD required)

August saw a sharp decline in CNS clinical development openings, suggesting a cautious approach by companies as they refine R&D priorities. This slowdown may drive greater competition for specialized talent as organizations seek to consolidate expertise for critical projects presenting an opportunity for standout candidates to shine in a more selective hiring environment.

CNS/NEURO FUNDING, MERGERS, & WORKFORCE UPDATES

Avidity raises $345.1M following positive Phase 1/2 trial results for DMD. LEARN MORE

Ultragenyx secures $14M in seed funding for its Alzheimer's gene therapy subsidiary Amlogenyx. LEARN MORE

Genentech partners with Sanagamo in a deal worth $50M upfront for exclusive rights to proprietary Alzheimer's treatment. LEARN MORE

UCB sells its Chinese neurology and allergy business to Mubadala and CBC for $680M. LEARN MORE

CNS EXECUTIVE MOVES

Ventyx appoints Mark Forman, MD PhD, as Chief Medical Officer

Dyne Therapeutics appoints Doug Kerr, MD PhD MBA, as Chief Medical Officer

Actio appoints pediatric neurologist Dimitrios Arkilo, MD, as Chief Medical Officer

Cerevance appoints Sagar Vaidya, MD PhD, as Chief Medical Officer

Neuvivo appoints Matthew W. David, MD RPh, as Chief Medical Officer

Ovid appoints Amanda Banks, MD, as Chief Development Officer

Passage Bio appoints Susan Browne, PhD, as Chief Scientific Officer

Ultragenyx appoints David Jacoby, MD, PhD, SVP, Head of Clinical Development

NOTEWORTHY DATA UPDATES

ABA-101 given FDA Fast Track designation for treatment of multiple sclerosis

FDA approves Crexont extended-release capsules for treatment of Parkinson's

Positive Phase 1/2 trial results reported for Duchenne muscular dystrophy drug

FDA withholds approval of MDA-assisted therapy for PTSD; requests more safety data

WVE-N531 granted Rare Pediatric Disease

designation by FDA for treatment of boys with DMD

ABOUT OUR FIRM

Fairway Consulting Group has been ranked by Forbes as one of America's Best Executive Recruiting Firms 4 years in a row.

Hunt Scanlon has consistently ranked Fairway Consulting Group in their list of

Top 40 Life Science Search Firms.

LEARN MORE ABOUT US